Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Areteia Therapeutics is a biotechnology company committed to putting asthma patients in better control of their disease.
SpringWorks Therapeutics is a biopharmaceutical company that develops medicines for patients with severe rare diseases and cancer.
Eyebiotech is an ophthalmology biotechnology company that specializes in therapies for eye diseases.
Aiolos Bio is a biotech company developing innovative therapies for respiratory diseases and immune conditions.
Alkeus Pharmaceuticals is a Boston-based startup focused on treatments for serious ophthalmic conditions.
Jnana Therapeutics develops innovative therapies using a chemoproteomics drug discovery platform.
Aptinyx Inc. is a biopharmaceutical company.
River 2 Renal is a developer of novel therapies intended to cure orphan diseases.
AavantiBio is a biopharmaceutical company that provides gene transfer and gene editing therapies to treat genetic diseases.
Bain Capital Life Sciences has invested in 57 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Bain Capital Life Sciences's top investment sectors include Biotechnology, Health Care, Medical, Therapeutics, Biopharma. The firm invests across 9 different industry categories.
Among tracked funding rounds, SpringWorks Therapeutics received $275.0M in a Post Ipo Equity round. Bain Capital Life Sciences's total known invested capital is $9.0B.
Bain Capital Life Sciences's average investment size is $163.2M across its portfolio of 57 companies.
Recent Bain Capital Life Sciences portfolio additions include Areteia Therapeutics, SpringWorks Therapeutics, Eyebiotech, Aiolos Bio, Alkeus Pharmaceuticals. These companies were founded in 2020 or later.